BiotechTube
Home/GRAIL/Josh Ofman, MD, MSHS
JO

Josh Ofman, MD, MSHS

Chief Executive Officer

GRAIL

Therapeutic Areas

Oncology

GRAIL Pipeline

DrugIndicationPhase
NHS-Galleri TrialMulti-Cancer Population ScreeningRandomized Controlled Trial
PATHFINDER 2Multi-Cancer Early DetectionInterventional Study
REACH/Galleri-Medicare StudyMulti-Cancer Early DetectionProspective Cohort Study
REFLECTION StudyMulti-Cancer Early DetectionObservational Study
SUMMIT StudyMulti-Cancer Early DetectionObservational Cohort Study
STRIVE StudyMulti-Cancer Early Detection in WomenObservational Cohort Study
CCGA StudyBiomarker Discovery & ValidationObservational Case-Control Study
PATHFINDER StudyMulti-Cancer Early DetectionInterventional Study

Leadership Team at GRAIL

BR
Bob Ragusa
Former Chief Executive Officer
View full GRAIL profile